WILMINGTON, Del., Nov. 10, 2026 (GLOBE NEWSWIRE) -- Exicure, Inc. (Nasdaq: XCUR) (“Exicure” or the “Company”) today announced that on November 4, 2026, the Company and its wholly owned subsidiary, GPCR Therapeutics USA Inc. (“GPCR USA”), entered into an Intellectual Property, Asset and License Assignment Agreement (the “Agreement”) with GPCRT Inc. (“GPCRT”), a company organized under the laws of the Republic of Korea, under which GPCRT has agreed to acquire the Company’s GPC-100 (burixafor) prog
This is the newest page. Registered accounts read further back.